Hilltop Holdings Inc. Raises Stock Holdings in Abbott Laboratories $ABT

Hilltop Holdings Inc. raised its stake in Abbott Laboratories (NYSE:ABT) by 226.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,681 shares of the healthcare product maker’s stock after purchasing an additional 6,719 shares during the period. Hilltop Holdings Inc.’s holdings in Abbott Laboratories were worth $994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of ABT. Orleans Capital Management Corp LA increased its position in shares of Abbott Laboratories by 2.2% during the first quarter. Orleans Capital Management Corp LA now owns 15,941 shares of the healthcare product maker’s stock worth $1,637,000 after purchasing an additional 340 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Abbott Laboratories by 217.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker’s stock worth $566,967,000 after buying an additional 3,780,402 shares during the last quarter. Caxton Associates LLP purchased a new stake in Abbott Laboratories in the first quarter valued at about $290,000. Dickmeyer Boyce Financial Management Inc. acquired a new position in shares of Abbott Laboratories during the first quarter valued at about $829,000. Finally, Ascension Capital Advisors Inc. purchased a new stake in Abbott Laboratories during the 1st quarter worth approximately $459,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $103.13 on Monday. The company has a market capitalization of $179.63 billion, a P/E ratio of 33.38, a P/E/G ratio of 2.00 and a beta of 0.61. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The business’s 50 day moving average is $91.61 and its two-hundred day moving average is $101.16. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The firm’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Raymond James Financial cut their target price on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Weiss Ratings lowered Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research report on Friday, July 17th. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Robert W. Baird started coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.